Clinical efficacy of fecal microbial transplantation treatment in adults with moderate‐to‐severe atopic dermatitis

Mashiah, Jacob; Karady, Tal; Fliss-Isakov, Naomi; Sprecher, Eli; Slodownik, Dan; Artzi, Ofir; Samuelov, Liat; Ellenbogen, Eran; Godneva, Anastasia; Segal, Eran; Maharshak, Nitsan

doi:10.1002/iid3.570

Cited by 38 publications

(45 citation statements)

References 41 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…That the gut microbiota is an important player in the disease pathogenesis was recently shown by interventional studies using fecal microbial transplantation (FMT) in patients with AD. These studies showed that FMT is safe and efficacious in controlling clinical signs of AD in dogs and humans [ 32 , 33 ]. Therefore, there is a high need for future studies in this field.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the Gut Microbiome between Atopic and Healthy Dogs—Preliminary Data

Rostaher

Morsy

Favrot

et al. 2022

Animals

View full text Add to dashboard Cite

Human studies show that in addition to skin barrier and immune cell dysfunction, both the cutaneous and the gut microbiota can influence the pathogenesis of atopic diseases. There is currently no data on the gut-skin axis in allergic canines. Therefore, the aim of this study was to assess the bacterial diversity and composition of the gut microbiome in dogs with atopic dermatitis (AD). Stool samples from adult beagle dogs (n = 3) with spontaneous AD and a healthy control group (n = 4) were collected at Days 0 and 30. After the first sampling, allergic dogs were orally dosed on a daily basis with oclacitinib for 30 days, and then re-sampled. Sequencing of the V3–V4 region of the 16S rRNA gene was performed on the Illumina MiSeq platform and the data were analyzed using QIIME2. The atopic dogs had a significantly lower gut microbiota alpha-diversity than healthy dogs (p = 0.033). In healthy dogs, a higher abundance of the families Lachnospiraceae (p = 0.0006), Anaerovoracaceae (p = 0.006) and Oscillospiraceae (p = 0.021) and genera Lachnospira (p = 0.022), Ruminococcustorques group (p = 0.0001), Fusobacterium (p = 0.022) and Fecalibacterium (p = 0.045) was seen, when compared to allergic dogs. The abundance of Conchiformibius (p = 0.01), Catenibacterium spp. (p = 0.007), Ruminococcus gnavus group (p = 0.0574) and Megamonas (p = 0.0102) were higher in allergic dogs. The differences in alpha-diversity and on the compositional level remained the same after 1 month, adding to the robustness of the data. Additionally, we could also show that a 4-week treatment course with oclacitinib was not associated with changes in the gut microbiota diversity and composition in atopic dogs. This study suggests that alterations in the gut microbiota diversity and composition may be associated with canine AD. Large-scale studies preferably associated to a multi-omics approach and interventions targeting the gut microbiota are needed to confirm these results.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of the Gut Microbiome between Atopic and Healthy Dogs—Preliminary Data

Rostaher

Morsy

Favrot

et al. 2022

Animals

View full text Add to dashboard Cite

show abstract

“…Compared to baseline pre-FMT, the authors reported a decrease in corticosteroid usage, a decrease in disease severity, and the patient’s gut microbiota profile becoming similar to the donor’s. Interestingly, the level of similarity correlated with the decreases in disease severity, namely, the more the profile was similar to the donor and the more the severity decreased [ 206 ]. Despite the variability of the results obtained in a small cohort of patients, this is the first clinical evidence demonstrating promising FMT-based therapy perspectives for the treatment of atopic dermatitis.…”

Section: Fecal Microbiota Transplantation In Human Diseasesmentioning

confidence: 99%

Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases

Biazzo

Deidda

2022

JCM

View full text Add to dashboard Cite

The human body is home to a variety of micro-organisms. Most of these microbial communities reside in the gut and are referred to as gut microbiota. Over the last decades, compelling evidence showed that a number of human pathologies are associated with microbiota dysbiosis, thereby suggesting that the reinstatement of physiological microflora balance and composition might ameliorate the clinical symptoms. Among possible microbiota-targeted interventions, pre/pro-biotics supplementations were shown to provide effective results, but the main limitation remains in the limited microbial species available as probiotics. Differently, fecal microbiota transplantation involves the transplantation of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient’s gut microbial composition aiming to confer a health benefit. Firstly used in the 4th century in traditional Chinese medicine, nowadays, it has been exploited so far to treat recurrent Clostridioides difficile infections, but accumulating data coming from a number of clinical trials clearly indicate that fecal microbiota transplantation may also carry the therapeutic potential for a number of other conditions ranging from gastrointestinal to liver diseases, from cancer to inflammatory, infectious, autoimmune diseases and brain disorders, obesity, and metabolic syndrome. In this review, we will summarize the commonly used preparation and delivery methods, comprehensively review the evidence obtained in clinical trials in different human conditions and discuss the variability in the results and the pivotal importance of donor selection. The final aim is to stimulate discussion and open new therapeutic perspectives among experts in the use of fecal microbiota transplantation not only in Clostridioides difficile infection but as one of the first strategies to be used to ameliorate a number of human conditions.

show abstract

“…Indeed, evidence has suggested that oral supplementation of Lactobacillus and Bifidobacterium strains could reduce the risk of AD in infants by regulating T cell-mediated responses [157]. FMT, as the most direct approach of modulating gut microbiota, is reported to be associated with suppression of AD-induced allergic responses by restoration of gut microbiota and immunological balance both in human and animal studies [158,159].…”

Section: The Role Of Skin and Gut Microbiota In Atopic Dermatitismentioning

confidence: 99%

The Role of Early Life Microbiota Composition in the Development of Allergic Diseases

Tuniyazi

et al. 2022

Microorganisms

View full text Add to dashboard Cite

Allergic diseases are becoming a major healthcare issue in many developed nations, where living environment and lifestyle are most predominantly distinct. Such differences include urbanized, industrialized living environments, overused hygiene products, antibiotics, stationary lifestyle, and fast-food-based diets, which tend to reduce microbial diversity and lead to impaired immune protection, which further increase the development of allergic diseases. At the same time, studies have also shown that modulating a microbiocidal community can ameliorate allergic symptoms. Therefore, in this paper, we aimed to review recent findings on the potential role of human microbiota in the gastrointestinal tract, surface of skin, and respiratory tract in the development of allergic diseases. Furthermore, we addressed a potential therapeutic or even preventive strategy for such allergic diseases by modulating human microbial composition.

show abstract

Clinical efficacy of fecal microbial transplantation treatment in adults with moderate‐to‐severe atopic dermatitis

Cited by 38 publications

References 41 publications

Comparison of the Gut Microbiome between Atopic and Healthy Dogs—Preliminary Data

Comparison of the Gut Microbiome between Atopic and Healthy Dogs—Preliminary Data

Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases

The Role of Early Life Microbiota Composition in the Development of Allergic Diseases

Contact Info

Product

Resources

About